ClinicalTrials.gg
CompletedNCT04560998STRIDEUpdated Jun 5, 2026Results posted

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Diabetes Mellitus, Type 2 and Peripheral Arterial Disease, sponsored by Novo Nordisk A/S. Completed at 283 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
22nd of 163
792 · median 104
Started
2020
with 8 others
Phase 3
57 of 163
7 open now
Registered
79th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment, is one of 9 that started in 2020, is one of 57 in phase 3, and was the 79th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age above or equal to 18 years at the time of signing . For Japan: Male or female, age above or equal to 20 years at time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.
  • Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa (Rutherford classification grade I, category 1 and 2) meeting all of the following:

    1. Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m/656 feet/2 blocks) for at least 90 days prior to the day of screening based on patient interview.
    2. Screening flat treadmill test (3.2 km/h (2 mph)): Pain-free walking distance of at least 200 meters/656 feet.
    3. Screening constant load treadmill test with fixed inclination of 12% and a fixed speed of 3.2 km/h (2 mph): Walking distance equal to or less than 600 meters/1968 feet.
    4. Ankle-brachial-index (ABI) equal to or below 0.90 or toe-brachial index (TBI) equal to or below 0.7 (the leg with lowest index is chosen in case of bilateral disease).

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with any GLP-1 receptor agonist (GLP-1-RA) within 90 days prior to the day of screening.
  • Walking ability limited by conditions other than PAD (e.g. aortic aneurism, dysregulated arrhythmia or hypertension, angina pectoris, heart failure, chronic obstructive or restrictive pulmonary disease, Parkinson's disease, severe peripheral neuropathy, amputations, wheel chair or walker dependency, osteoarthritis, morbid obesity, severe varicose veins, etc.).
  • Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability).
  • Vascular revascularisation procedure of any kind 180 days prior to the day of screening.
  • Planned arterial revascularisation known on the day of screening.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Heart failure presently classified as being in (NYHA) class III-IV.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
792 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Semaglutide given in addition to standard-of-care treatment

    Drug: Semaglutide

  • Placebo comparator
    Placebo (semaglutide)

    Placebo given in addition to standard-of-care treatment

    Drug: Placebo (semaglutide)

Interventions

  • Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.

  • DrugPlacebo (semaglutide)

    Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.

06

What researchers measure

Primary outcomes

  1. Change in Maximum Walking Distance on a Constant Load Treadmill Test

    Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Time frame: Baseline (week 0), end of treatment (week 52)

Secondary outcomes

  1. Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test

    Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, which-ever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Time frame: Baseline (week 0), end of follow-up (week 57)

  2. Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score

    Change in VascuQoL-6 score is presented. VascuQoL-6 is a peripheral artery disease-specific questionnaire with 6 items covering social, emotional, functional as well as pain- and symptom-related aspects of the patient´s overall quality of life. Each item has a 4-point response scale (where 1 = worst score and 4 = best score). The endpoint analysed is the total score (range: 6-24) generated by summing the scores from all items. A higher score indicates better health status. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Time frame: Baseline (week 0), end of treatment (week 52)

  3. Change in Pain-free Walking Distance on a Constant Load Treadmill Test

    Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stopping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Time frame: Baseline (week 0), end of treatment (week 52)

  4. Follow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test

    Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stop-ping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Time frame: Baseline (week 0), end of follow-up (week 57)

  5. Change in Glycosylated Haemoglobin (HbA1c)

    Change in HbA1c from baseline to week 52 in percentage-point is presented. The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  6. Change in Body Weight

    Change in body weight from baseline to week 52 in kilogram (kg) is presented. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  7. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline to week 52 is presented.The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  8. Change in Total Cholesterol

    Change in total cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  9. Change in Low-density Lipoprotein (LDL)-Cholesterol

    Change in LDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  10. Change in High Density Lipoprotein (HDL)-Cholesterol

    Change in HDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  11. Change in Triglycerides

    Change in Triglycerides from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  12. Change in Ankle-Brachial Index (ABI)

    Change in ABI from baseline to week 52 is presented. ABI is calculated as a ratio of the higher ankle systolic pressure to the higher systolic pressure measured in both arms. ABI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. An ABI between 1.0 to 1.4 is considered the normal range. An ABI between 0.90 to 0.99 is considered borderline. An ABI less than 0.90 indicates peripheral artery disease (PAD). The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Screening (week -2), end of treatment (week 52)

  13. Change in Toe-Brachial Index (TBI)

    Change in TBI from baseline to week 52 is presented. TBI is calculated as a ratio of the toe systolic pressure to the higher systolic pressure measured in both arms. TBI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. A TBI range of above or equal to 0.7 is considered normal, whereas a TBI less than 0.7 is considered abnormal. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Screening (week -2), end of treatment (week 52)

  14. Change in Walking Impairment Questionnaire (WIQ) Global Score

    Change in WIQ global score from baseline to week 52 is presented. WIQ consists of three domains, speed, distance, and stair climbing, consisting of in total 14 questions. Each response is weighted based on the difficulty of the task. Domain scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Global score is calculated as the mean of the three domain scores (ranged from 0% to 100%). A global score of 0% represents inabil-ity to perform any of the tasks and 100% represents no difficulty with any of the tasks. Higher scores indicate better walking ability and less impairment. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

  15. Change in Short Form 36 (SF-36) Physical Functioning Domain

    Change in SF-36 physical functioning domain from baseline to week 52 is presented. SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2 (acute version) questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores (Range: 19.03 to 57.60) to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A positive change score indicates an improvement in participant health stats. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

    Time frame: Baseline (week 0), end of treatment (week 52)

07

Results

Posted Jul 8, 2025

Participant flow

The trial was conducted at 129 sites in 21 countries.

Participant flow — Overall Study
MilestoneSemaglutidePlacebo
Started396396
Full analysis set396396
Safety analysis set396395
Completed366379
Not completed3017
Withdrew: Withdrawal by subject1812
Withdrew: Lost to follow-up85
Withdrew: Physician decision40

Outcome measures

PrimaryChange in Maximum Walking Distance on a Constant Load Treadmill Test

Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Median · Ratio of maximum walking distance
Change in Maximum Walking Distance on a Constant Load Treadmill Test
Ratio of maximum walking distanceSemaglutidePlacebo
Change in Maximum Walking Distance on a Constant Load Treadmill Test1.21 (0.95 to 1.55)1.08 (0.86 to 1.36)
Statistical analysis
  • Semaglutide vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0004 · The hodges-lehmann estimate: 1.13 · 95% CI 1.056 to 1.211
SecondaryFollow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test

Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants continue on the treadmill after indicating onset of pain and should continue as long as possible until pain limits further activity. This distance is noted as the maximum walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, which-ever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

Time frame:
Baseline (week 0), end of follow-up (week 57)
Reported as:
Median · Ratio of maximum walking distance
Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test
Ratio of maximum walking distanceSemaglutidePlacebo
Follow-up Change in Maximum Walking Distance on a Constant Load Treadmill Test1.16 (0.92 to 1.48)1.10 (0.87 to 1.40)
Statistical analysis
  • Semaglutide vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0380 · The hodges-lehmann estimate: 1.08 · 95% CI 1.004 to 1.156
SecondaryChange in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score

Change in VascuQoL-6 score is presented. VascuQoL-6 is a peripheral artery disease-specific questionnaire with 6 items covering social, emotional, functional as well as pain- and symptom-related aspects of the patient´s overall quality of life. Each item has a 4-point response scale (where 1 = worst score and 4 = best score). The endpoint analysed is the total score (range: 6-24) generated by summing the scores from all items. A higher score indicates better health status. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Median · Scores on a scale
Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score
Scores on a scaleSemaglutidePlacebo
Change in Vascular Quality of Life Questionnaire-6 (VascuQoL-6) Score2.0 (0.00 to 4.00)1.0 (-1.00 to 4.00)
Statistical analysis
  • Semaglutide vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0108 · The hodges-lehmann estimate: 1.00 · 95% CI 0.478 to 1.518
SecondaryChange in Pain-free Walking Distance on a Constant Load Treadmill Test

Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stopping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Median · Ratio of pain-free walking distance
Change in Pain-free Walking Distance on a Constant Load Treadmill Test
Ratio of pain-free walking distanceSemaglutidePlacebo
Change in Pain-free Walking Distance on a Constant Load Treadmill Test1.21 (0.92 to 1.52)1.10 (0.86 to 1.44)
Statistical analysis
  • Semaglutide vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0046 · The hodges-lehmann estimate: 1.11 · 95% CI 1.033 to 1.197
SecondaryFollow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test

Change in pain-free walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is a standardised method for functional assessment of patients with peripheral artery disease. Participants are instructed to when pain starts in either leg and to continue on the treadmill without stop-ping at this stage. The distance walked is noted as the pain-free walking distance. The outcome measure was evaluated based on data from in-study observation period. In-study observation period is defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

Time frame:
Baseline (week 0), end of follow-up (week 57)
Reported as:
Median · Ratio of pain-free walking distance
Follow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test
Ratio of pain-free walking distanceSemaglutidePlacebo
Follow-up Change in Pain-free Walking Distance on a Constant Load Treadmill Test1.18 (0.92 to 1.59)1.10 (0.83 to 1.48)
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Change in HbA1c from baseline to week 52 in percentage-point is presented. The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Percentage-point of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage-point of HbA1cSemaglutidePlacebo
Change in Glycosylated Haemoglobin (HbA1c)-0.8 ± 1.10.2 ± 1.1
SecondaryChange in Body Weight

Change in body weight from baseline to week 52 in kilogram (kg) is presented. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)SemaglutidePlacebo
Change in Body Weight-5.2 ± 4.8-1.2 ± 4.2
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline to week 52 is presented.The outcome measure is evaluated based on the on treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Millimetre of mercury (mmHg)
Change in Systolic Blood Pressure
Millimetre of mercury (mmHg)SemaglutidePlacebo
Change in Systolic Blood Pressure-4 ± 15-1 ± 18
SecondaryChange in Total Cholesterol

Change in total cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Total Cholesterol
Ratio of total cholesterolSemaglutidePlacebo
Change in Total Cholesterol0.96 ± 20.181.00 ± 19.88
SecondaryChange in Low-density Lipoprotein (LDL)-Cholesterol

Change in LDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of LDL
Change in Low-density Lipoprotein (LDL)-Cholesterol
Ratio of LDLSemaglutidePlacebo
Change in Low-density Lipoprotein (LDL)-Cholesterol0.99 ± 38.371.03 ± 42.27
SecondaryChange in High Density Lipoprotein (HDL)-Cholesterol

Change in HDL-cholesterol from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of HDL
Change in High Density Lipoprotein (HDL)-Cholesterol
Ratio of HDLSemaglutidePlacebo
Change in High Density Lipoprotein (HDL)-Cholesterol1.04 ± 15.950.99 ± 13.91
SecondaryChange in Triglycerides

Change in Triglycerides from baseline to week 52 is presented as ratio to baseline. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Triglycerides
Ratio of triglyceridesSemaglutidePlacebo
Change in Triglycerides0.80 ± 45.950.95 ± 41.73
SecondaryChange in Ankle-Brachial Index (ABI)

Change in ABI from baseline to week 52 is presented. ABI is calculated as a ratio of the higher ankle systolic pressure to the higher systolic pressure measured in both arms. ABI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. An ABI between 1.0 to 1.4 is considered the normal range. An ABI between 0.90 to 0.99 is considered borderline. An ABI less than 0.90 indicates peripheral artery disease (PAD). The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Screening (week -2), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of ABI
Change in Ankle-Brachial Index (ABI)
Ratio of ABISemaglutidePlacebo
Change in Ankle-Brachial Index (ABI)1.06 ± 34.01.02 ± 19.6
SecondaryChange in Toe-Brachial Index (TBI)

Change in TBI from baseline to week 52 is presented. TBI is calculated as a ratio of the toe systolic pressure to the higher systolic pressure measured in both arms. TBI is measured at both left and right leg and the analysis endpoint is defined as the lower of the two indices. A TBI range of above or equal to 0.7 is considered normal, whereas a TBI less than 0.7 is considered abnormal. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Screening (week -2), end of treatment (week 52)
Reported as:
Geometric mean · Ratio of TBI
Change in Toe-Brachial Index (TBI)
Ratio of TBISemaglutidePlacebo
Change in Toe-Brachial Index (TBI)1.07 ± 34.41.04 ± 37.3
SecondaryChange in Walking Impairment Questionnaire (WIQ) Global Score

Change in WIQ global score from baseline to week 52 is presented. WIQ consists of three domains, speed, distance, and stair climbing, consisting of in total 14 questions. Each response is weighted based on the difficulty of the task. Domain scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Global score is calculated as the mean of the three domain scores (ranged from 0% to 100%). A global score of 0% represents inabil-ity to perform any of the tasks and 100% represents no difficulty with any of the tasks. Higher scores indicate better walking ability and less impairment. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · %-point scores on a scale
Change in Walking Impairment Questionnaire (WIQ) Global Score
%-point scores on a scaleSemaglutidePlacebo
Change in Walking Impairment Questionnaire (WIQ) Global Score9.48 ± 18.636.51 ± 20.53
SecondaryChange in Short Form 36 (SF-36) Physical Functioning Domain

Change in SF-36 physical functioning domain from baseline to week 52 is presented. SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2 (acute version) questionnaire measured 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores (Range: 19.03 to 57.60) to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A positive change score indicates an improvement in participant health stats. The outcome measure is evaluated based on the on-treatment without rescue treatment observation period. This period includes assessments and events for the time period where participants were exposed to trial product and before rescue treatment (medication or revascularisation procedure).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Scores on a scale
Change in Short Form 36 (SF-36) Physical Functioning Domain
Scores on a scaleSemaglutidePlacebo
Change in Short Form 36 (SF-36) Physical Functioning Domain2.98 ± 7.321.52 ± 7.17

Adverse events

Collected over Until week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide4/396 (1%)74/396 (18.7%)47/396 (11.9%)
Placebo9/395 (2.3%)78/395 (19.7%)24/395 (6.1%)
Most frequent serious events
Showing 10 of 150
Most frequent serious events
EventSemaglutidePlacebo
Acute myocardial infarctionCardiac disorders3/3965/395
Peripheral arterial occlusive diseaseVascular disorders4/3965/395
PneumoniaInfections and infestations0/3965/395
Coronary artery diseaseCardiac disorders4/3960/395
Cerebral infarctionNervous system disorders3/3963/395
Peripheral ischaemiaVascular disorders1/3963/395
Acute kidney injuryRenal and urinary disorders3/3960/395
Angina unstableCardiac disorders3/3962/395
Coronary artery stenosisCardiac disorders3/3960/395
DiverticulitisInfections and infestations3/3961/395
Most frequent other events
Most frequent other events
EventSemaglutidePlacebo
COVID-19Infections and infestations30/39621/395
NauseaGastrointestinal disorders22/3963/395

Baseline characteristics

The full analysis set (FAS) included all randomised participants. All participants were analyzed according to the treatment to which they were assigned at randomisation

Age, Continuous
Age, Continuous(Years)SemaglutidePlaceboTotal
Mean66.2 ± 9.7167.0 ± 8.9666.6 ± 9.35
Sex: Female, Male
Sex: Female, Male(Participants)SemaglutidePlaceboTotal
Female10788195
Male289308597
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SemaglutidePlaceboTotal
Hispanic or Latino7613
Not Hispanic or Latino388385773
Unknown or Not Reported156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SemaglutidePlaceboTotal
American Indian or Alaska Native011
Asian131109240
Native Hawaiian or Other Pacific Islander101
Black or African American448
White259279538
Other134
08

Study locations

283 sites
  • Cardiology, PC
    Birmingham, Alabama 35211, United States
  • Cardiovascular Associates of the Southeast
    Birmingham, Alabama 35243, United States
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Chandler Regional Medical Center
    Chandler, Arizona 85224, United States
  • Abrazo Diabetes Care Center
    Glendale, Arizona 85308, United States
  • Central Arkansas Veteran's Healthcare System
    Little Rock, Arkansas 72205, United States
  • Cardio Innovation & Resch Ctr
    Long Beach, California 90813, United States
  • Angel City Research, Inc.
    Los Angeles, California 90010, United States
  • St. Joseph Heritage Healthcare_Mission Viejo
    Mission Viejo, California 92691, United States
  • Adventist Hlth St Helena Hosp
    St. Helena, California 94574, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Stanford University_Stanford
    Stanford, California 94305, United States
  • Rocky Mount Reg VA Med-DN
    Aurora, Colorado 80045, United States
  • UC Health Heart & Vascular Center
    Aurora, Colorado 80045, United States
  • Univ of Colorado at Denver
    Aurora, Colorado 80045, United States
  • Bay Area Cardiology Associates, P.A.
    Brandon, Florida 33511, United States
  • Clearwater Cardiovascular Consultants
    Clearwater, Florida 33756, United States
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • CV Res Ctr of S Florida
    Miami, Florida 33173, United States
  • Cardiovascular Institute of Central Florida
    Ocala, Florida 34471, United States
  • DMI Research
    Pinellas Park, Florida 33782, United States
  • Cardiovascular Ctr of Sarasota
    Sarasota, Florida 34239, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Accel Research Site-Georgia
    Eatonton, Georgia 31024, United States
  • Reg Infectious Dis Infuse Ctr
    La Grange, Georgia 30240, United States
  • Aiyan Diabetes Center
    Martinez, Georgia 30907, United States
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
  • Northwestern University_Chicago
    Chicago, Illinois 60611, United States
  • Endeavor Health Glenbook Hosp
    Glenview, Illinois 60026, United States
  • Central IL Diabetes and Clinical Research
    Springfield, Illinois 62701, United States
  • Cardiovascular Rsrch of NW_IN
    Munster, Indiana 46321, United States
  • Central Cardio Assoc HPS
    Elizabethtown, Kentucky 42701, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • LOUISIANA HEART Center
    Covington, Louisiana 70433, United States
  • Clinical Trials of Ame, LLC
    Monroe, Louisiana 71201, United States
  • Ascension Saint Agnes Heart Ca
    Baltimore, Maryland 21229, United States
  • Boston Medical Center_Boston_1
    Boston, Massachusetts 02118, United States
  • Boston Medical Center_Cary
    Boston, Massachusetts 02118, United States
  • Steward St. Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Minneapolis Cardiology Assoc
    Minneapolis, Minnesota 55407-1195, United States
  • University of Minnesota_Minneapolis_1
    Minneapolis, Minnesota 55455, United States
  • Amicis Centers of Clinical Research
    St Louis, Missouri 63128, United States
  • Nebraska West Iowa Hlth System
    Omaha, Nebraska 68105, United States
  • Methodist Phys Clin Heart Cons
    Omaha, Nebraska 68114, United States
  • Dartmouth-Hitchcock Med Ctr
    Lebanon, New Hampshire 03766, United States
  • NJ Heart
    Linden, New Jersey 07036, United States
  • NYU Langone Med Assoc Chelsea
    New York, New York 10001, United States
  • Mount Sinai Hosp at NYC
    New York, New York 10029, United States
  • UNC- Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • NC Heart and Vascular Research
    Raleigh, North Carolina 27607, United States
  • Accellacare_NC
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Mount Carmel Heart and Vascular
    Columbus, Ohio 43213, United States
  • Advanced Med Res Maumee
    Maumee, Ohio 43537, United States
  • South Oklahoma Heart Research, LLC
    Oklahoma City, Oklahoma 73135, United States
  • Capital Area Research LLC
    Camp Hill, Pennsylvania 17011, United States
  • Penn Presb Med Ctr
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson Univ Di Rsrch Ctr
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Vanderbilt U Med Ctr_Nashville
    Nashville, Tennessee 37232, United States
  • PharmaTex Research
    Amarillo, Texas 79106, United States
  • St. David's Medical Center
    Austin, Texas 78705, United States
  • Soltero Cardiovascular Research Center
    Dallas, Texas 75226, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030-2703, United States
  • Northwest Houston Cardiology, P.A.
    Houston, Texas 77070, United States
  • Houston Heart & Vascular Associates
    Humble, Texas 77338, United States
  • Texas Cardiology Associates of Houston
    Kingwood, Texas 77339, United States
  • Texas Tech University Health Science Center
    Lubbock, Texas 79430-8183, United States
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Univ Of Texas Hlth Science Cntr
    San Antonio, Texas 78229, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • San Antonio Endovascular and Heart Institute
    San Antonio, Texas 78258, United States
  • Cardiovascular Associates East Texas
    Tyler, Texas 75701, United States
  • Victoria Heart and Vasc Ctr
    Victoria, Texas 77901, United States
  • Alpine Research Organization Inc
    Farmington, Utah 84025, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042-3300, United States
  • Carient Heart and Vascular
    Manassas, Virginia 20109, United States
  • Roanoke Heart Institute
    Roanoke, Virginia 24014, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Winchester Medical Center
    Winchester, Virginia 22601, United States
  • Aspirus Research Institute
    Wausau, Wisconsin 54401, United States
  • Universitätsklinik für Innere Medizin Graz
    Graz, 8036, Austria
  • Univ.-Klinik für Innere Medizin III
    Innsbruck, 6020, Austria
  • Klinik Landstraße
    Vienna, 1030, Austria
  • AKH Wien
    Vienna, 1090, Austria
  • Imeldaziekenhuis Bonheiden - Thoracic and Vascular Surgery
    Bonheiden, 2820, Belgium
  • Ziekenhuis Oost-Limburg AV - Thoracic
    Genk, 3600, Belgium
  • UZ Gent - Thoracale Vasculaire Heelkunde
    Ghent, 9000, Belgium
  • UZ Gent_Gent_1
    Ghent, 9000, Belgium
  • AZ Groeninge - Thoracic Vascular Surgery
    Kortrijk, 8500, Belgium
  • UZ Leuven - Hart en Vaatziekten
    Leuven, 3000, Belgium
  • St Pauls Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 0N2, Canada

Showing the first 100 of 283 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S; STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4. Epub 2025 Mar 29. PubMed 40169145 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2024, 44 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 44 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 23, 2020
StartActual
Oct 1, 2020
Primary completionActual
Jun 5, 2024
CompletionActual
Jul 12, 2024
Results first posted
Jul 8, 2025
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04560998
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
Oct 1, 2020
Primary completion
Jun 5, 2024
Completion
Jul 12, 2024
Results posted
Jul 8, 2025
Last update
Jun 5, 2026

Study contacts

Clinical Transparency (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion